37 completed, 16 terminated, 7 active not recruiting, 5 recruiting. 43 Phase 1, 30 Phase 2, 5 Phase 3, 1 Early Phase 1.
Follow Celldex Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of CDX-622 in Participants With Mild to Moderate Asthma CDX-622 - Mild to Moderate Asthma | Phase 1 | Recruiting | Celldex Therapeutics | 12 | 2026-06-01 | 2026-07-02 |
| A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD) Barzolvolimab, Matching Placebo - Chronic Inducible Urticaria, Cold Urticaria | Phase 3 | Recruiting | Celldex Therapeutics | 240 | 2026-01-15 | 2026-10-07 |
| Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria barzolvolimab, Standard of Care - Chronic Spontaneous Urticaria | Phase 3 | Enrolling by invitation | Celldex Therapeutics | 1370 | 2025-11-25 | 2026-10-07 |
| A Study of Barzolvolimab in Patients With Atopic Dermatitis Barzolvolimab, Matching placebo - Atopic Dermatitis | Phase 2 | Active not recruiting | Celldex Therapeutics | 131 | 2024-12-18 | 2026-08-11 |
| A Phase I Study of CDX-622 CDX-622, Normal Saline - Healthy Participants | Phase 1 | Completed | Celldex Therapeutics | 85 | 2024-11-01 | 2026-05-04 |
| A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU) barzolvolimab, Matching placebo - Chronic Spontaneous Urticaria | Phase 3 | Active not recruiting | Celldex Therapeutics | 976 | 2024-07-19 | 2026-03-25 |
| A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria barzolvolimab, Matching placebo - Chronic Spontaneous Urticaria | Phase 3 | Active not recruiting | Celldex Therapeutics | 963 | 2024-07-11 | 2026-03-25 |
| A Study of Barzolvolimab in Patients With Prurigo Nodularis barzolvolimab, Matching Placebo - Prurigo Nodularis | Phase 2 | Active not recruiting | Celldex Therapeutics | 140 | 2024-04-12 | 2026-08-04 |
| Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Bevacizumab, Pembrolizumab - Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 80 | 2024-03-12 | 2026-08-14 |
| A Study of CDX-0159 in Patients With Eosinophilic Esophagitis barzolvolimab, Matching Placebo - Eosinophilic Esophagitis | Phase 2 | Completed | Celldex Therapeutics | 86 | 2023-06-01 | 2026-05-27 |
| A Study of CDX-585 in Patients With Advanced Malignancies CDX-585 - Non-small Cell Lung Cancer, Gastric Cancer | Phase 1 | Completed | Celldex Therapeutics | 20 | 2023-05-11 | 2025-06-15 |
| Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T) TCR-transduced T cells, CDX-1140, Pembrolizumab - Malignant Epithelial Neoplasms | Phase 1 | Active not recruiting | Providence Health & Services | 1 | 2023-04-03 | 2026-04-24 |
| A Maintenance Therapy Study of Odetiglucan With CDX-1140 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma odetiglucan, CDX-1140 - Metastatic Pancreatic Adenocarcinoma | Phase 1 | Terminated | HiberCell, Inc. | 5 | 2022-12-15 | 2024-04-10 |
| A Study of CDX-0159 in Patients With Chronic Inducible Urticaria barzolvolimab, Matching Placebo - Chronic Inducible Urticaria | Phase 2 | Completed | Celldex Therapeutics | 196 | 2022-06-28 | 2025-11-06 |
| A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria barzolvolimab, Matching Placebo - Chronic Spontaneous Urticaria | Phase 2 | Completed | Celldex Therapeutics | 208 | 2022-05-19 | 2025-03-26 |
| CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer PLD Chemotherapy, CDX-1140, CDX-301 - HER2-negative Breast Cancer, Metastatic Breast Cancer | Phase 1 | Recruiting | University of Texas Southwestern Medical Center | 30 | 2022-04-20 | 2026-06-17 |
| NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma CDX-301, NEOVAX, Nivolumab - Melanoma, Metastatic Melanoma | Phase 1 | Active not recruiting | Dana-Farber Cancer Institute | 10 | 2022-01-03 | 2026-03-25 |
| A Study of CDX-0159 in Patients With Prurigo Nodularis CDX-0159, Normal saline - Prurigo Nodularis | Phase 1 | Completed | Celldex Therapeutics | 24 | 2021-11-08 | 2023-08-14 |
| A Phase 1 Study of Subcutaneous CDX-0159 in Healthy Subjects CDX-0159, Normal saline - Healthy Subjects | Phase 1 | Completed | Celldex Therapeutics | 32 | 2021-08-30 | 2022-01-21 |
| Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients CDX-301, CDX-1140, Research blood draw - Pancreatic Cancer, Cancer of the Pancreas | Phase 2 | Terminated | Washington University School of Medicine | 16 | 2021-08-13 | 2024-10-08 |
Showing 20 of 69. Sign in to see all of them.
Breast Neoplasms (10) · Melanoma (10) · Ovarian Neoplasms (10) · Carcinoma, Non-Small-Cell Lung (8) · Carcinoma, Renal Cell (8) · Chronic Urticaria (5) · Colorectal Neoplasms (5) · Fallopian Tube Neoplasms (5) · Glioblastoma (5) · Pancreatic Neoplasms (5) · Urinary Bladder Neoplasms (5) · Esophageal Neoplasms (4) · Head and Neck Neoplasms (4) · Kidney Neoplasms (4) · Neoplasms (4)
poly ICLC (8) · pembrolizumab (7) · varlilumab (7) · glembatumumab vedotin (6) · Nivolumab (5) · Saline Solution (5) · rindopepimut (4) · Temozolomide (3) · Bevacizumab (2) · CDX 1307 (2) · Drug Therapy (2) · Granulocyte-Macrophage Colony-Stimulating Factor (2) · Radiosurgery (2) · flt3 ligand protein (2) · sargramostim (2)
United States (64) · Germany (13) · Spain (10) · Poland (9) · Canada (7) · United Kingdom (7) · Italy (6) · Australia (5) · Bulgaria (5) · Hungary (5) · South Africa (5) · Belgium (4) · France (4) · Georgia (4) · Lithuania (4)
Joshua Brody, MD (2) · Annick Desjardins, MD, FRCPC (1) · Carla Nester, MD, MSA (1) · Craig L Slingluff, Jr., MD (1) · Craig L. Slingluff, Jr., MD (1) · Elizabeth Griffiths (1) · Emese Zsiros (1) · Emese Zsiros, MD (1) · Eric Tran, PhD (1) · Hideho Okada, MD, PhD (1) · James Larner, MD (1) · Jeffrey Weber, MD (1) · Mark O'Hara (1) · Nicholas Butowski, MD (1) · Nitin Ohri, MD (1)
PMID 24739759, PMID 25586468, PMID 26670466, PMID 28844499, PMID 31308059, PMID 32034072, PMID 32380537, PMID 32472319, PMID 35045748, PMID 35940825, PMID 36346112, PMID 40809194, PMID 41747871, PMID 41775435
2023 (1), K08CA267189 (1), P30CA016056 (1), R01CA262506 (1), R21CA233856 (1)